Holen Sie sich die Stockscreener-App
1.69
4.32%
0.07
Handel nachbörslich:
1.55
-0.14
-8.28%
Schlusskurs vom Vortag:
$1.62
Offen:
$1.63
24-Stunden-Volumen:
78,822
Relative Volume:
0.04
Marktkapitalisierung:
$2.51M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-7.90M
KGV:
-0.00909
EPS:
-185.9263
Netto-Cashflow:
$-6.29M
1W Leistung:
+4.97%
1M Leistung:
-23.18%
6M Leistung:
-92.21%
1J Leistung:
-99.58%
1-Tages-Spanne:
$1.60
$1.705
1-Wochen-Bereich:
$1.43
$1.705
52-Wochen-Spanne:
$1.43
$524.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Firmenname
Clearmind Medicine Inc
Sektor
Branche
Telefon
-
Adresse
-
Compare CMND vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.69 | 2.41M | 0 | -7.90M | -6.29M | -185.93 |
VRTX
Vertex Pharmaceuticals Inc
|
477.10 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
762.63 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
853.82 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
187.53 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
316.01 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
Clearmind Medicine Inc Aktie (CMND) Neueste Nachrichten
Clearmind completes Part A of FDA-regulated tri... - Pluang
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - The Manila Times
Clearmind Medicine Completes Treatment of All Participants in Part A of Phase I/II AUD Trial for CMND-100 - Quiver Quantitative
Clearmind Medicine Successfully Completes Part A of its FDA Regulated Phase I/II Trial - GlobeNewswire Inc.
Clearmind Medicine Inc (CMND) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Clearmind Medicine Inc. Revenue Breakdown – FWB:CWY0 - TradingView
Clearmind Medicine Inc (CMND) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
TradingKey - TradingKey
Clearmind Medicine Inc (CMND) Valuation: PE, PB & Fair Value Analysis - TradingKey
Clearmind Medicine Inc (CMND) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Clearmind Medicine Inc (CMND) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
CMND|Clearmind Medicine Inc|Price:1.628|Chg%:+0.018 - TradingKey
CMND|Clearmind Medicine Inc|Price:1.615|Chg%:-0.045 - TradingKey
Clearmind Medicine Inc (CMND) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Clearmind Medicine Inc (CMND) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Clearmind Medicine (CMND) Stock Forecast & Analyst Ratings - Moomoo
Clearmind Medicine Inc. (CMND) Stock Price, News, Quote & History - Yahoo! Finance Canada
Clearmind files Hong Kong patent for PTSD treatment compounds - Investing.com
Clearmind Medicine Files Hong Kong Patent Application for PTSD-Targeting Compounds - Quiver Quantitative
Clearmind's PTSD Filing Targets Market Projected at $30.2B - Stock Titan
Clearmind submits addiction treatment proposal to U.S. HHS By Investing.com - Investing.com Nigeria
Clearmind Medicine Expends Global IP Portfolio With Hong Kong Patent Filing for Novel Psychedelic Compounds; Targets Multi‐Billion‐Dollar PTSD Therapeutics Market - Moomoo
Clearmind Medicine comments on federal psychedelic guidance By Investing.com - Investing.com South Africa
Clearmind Medicine comments on federal psychedelic guidance - Investing.com UK
Clearmind Medicine Commends Federal Momentum in Advancing Psychedelic-Based Therapies for Mental Health and Addiction - The Manila Times
Clearmind reports mucoadhesion results for intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine Reports Positive Retention Results for Intranasal Formulation of its Psychedelic-Based Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Reports Improved Mucoadhesion for Intranasal MEAI Formulation in Ex Vivo Study - Quiver Quantitative
Clearmind's MEAI formulation stayed longer on nasal tissue in testing - Stock Titan
Clearmind Medicine Inc. sees price surge amid market decline - Intellectia AI
Clearmind shares CMND-100 trial insights - grafa.com
Clearmind reports positive early data from alcohol disorder trial - Investing.com UK
Clearmind reports positive early data from alcohol disorder trial By Investing.com - Investing.com Canada
Clearmind's trial shows promising safety and po... - Pluang
Clearmind Medicine Reports Positive Early Experience in Phase I/IIa Trial of Non-Hallucinogenic MEAI for Alcohol Use Disorder - Quiver Quantitative
Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Yahoo Finance Singapore
Clearmind Medicine (CMND) Slides 1.93% as Shares Approach Critical $1.93 SupportVOLD Alert - dars.gov.et
Clearmind Medicine (Nasdaq: CMND) details neuroplastogen-based response to U.S. addiction RFI - Stock Titan
Clearmind Medicine Submits Formal Response To HHS RFI Highlighting MEAI-Based Candidate CMND-100 For Alcohol Use Disorder And Binge Behaviors - marketscreener.com
Clearmind submits addiction treatment proposal to U.S. HHS - Investing.com India
Clearmind submits MEAI addiction treatment prop... - Pluang
Clearmind Medicine Submits Response to HHS RFI Highlighting MEAI-Based CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Responds to the U.S. Administration’s RFI for Addiction Treatment Innovations as Part of the Great American Recovery Initiative - The Manila Times
Clearmind Medicine (CMND) reports successful intranasal MEAI feasibility study - Stock Titan
Clearmind reports MEAI intranasal study progress - grafa.com
Clearmind Medicine : Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration for MEAI - marketscreener.com
CMND Stock Slides As Traders Gauge Cash Runway And Volatility - StocksToTrade
Clearmind advances intranasal delivery studies for addiction drug By Investing.com - Investing.com Nigeria
Clearmind Reports Successful Formulation Feasibility Study Supporting Potential New Additional Route of Administration Development for MEAI - The Manila Times
Clearmind Medicine Reports Successful Formulation Feasibility for Intranasal MEAI Development Program for Alcohol Use Disorder - Quiver Quantitative
Clearmind Medicine Company Profile & Introduction - Moomoo
Finanzdaten der Clearmind Medicine Inc-Aktie (CMND)
Umsatz
Nettogewinn
Free Cashflow
ENV
Clearmind Medicine Inc-Aktie (CMND) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| HRT FINANCIAL LP | 10% Owner |
Jun 15 '26 |
Sale |
3.32 |
3,183 |
10,568 |
103,492 |
| HRT FINANCIAL LP | 10% Owner |
Jun 12 '26 |
Sale |
3.36 |
2,102 |
7,063 |
106,675 |
| HRT FINANCIAL LP | 10% Owner |
Jun 10 '26 |
Buy |
0.15 |
2,159,052 |
330,335 |
2,063,266 |
| HRT FINANCIAL LP | 10% Owner |
Jun 11 '26 |
Sale |
0.12 |
225,191 |
27,698 |
1,838,075 |
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):